News

PharmExec1h
Phase II Trial to Evaluate Boehringer Ingelheim’s First-in-Class Oral Therapy for Diabetic Macular Edema
The Phase II THULITE trial will analyze the safety and efficacy of BI 1815368, an investigational oral therapy designed to ...
PharmExec2h
FDA Grants Accelerated Approval to Regeneron’s Lynozyfic for Relapsed or Refractory Multiple Myeloma
Accelerated approval was based on results from the Phase I/II LINKER-MM1 trial, which showed a 70% objective response rate in ...
PharmExec3h
FDA Grants Priority Review to Merck’s Winrevair Label Update for Pulmonary Arterial Hypertension to Reflect Risk Reduction Benefits
Results from the Phase III ZENITH trial show that patients treated with Winrevair (sotatercept-csrk) for pulmonary arterial ...
PharmExec5h
Harmonizing the Payer Perspective with Real-World Evidence
Expert panelists emphasize the importance of trusted data sources, strong payer partnerships, economic incentives, and ...